Citations (193)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Riccardo Carloni, Simone Sabbioni, Alessandro Rizzo, Angela Dalia Ricci, Andrea Palloni, Cataldo Petrarota, Antonio Cusmai, Simona Tavolari, Gennaro Gadaleta-Caldarola & Giovanni Brandi. (2023) Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 10, pages 1445-1463.
Read now
Read now
Pierangela Sepe, Alessia Mennitto, Francesca Corti & Giuseppe Procopio. (2020) Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma. ImmunoTargets and Therapy 9, pages 273-288.
Read now
Read now
Shumei Kato, Ryosuke Okamura, Yuichi Kumaki, Sadakatsu Ikeda, Mina Nikanjam, Ramez Eskander, Aaron Goodman, Suzanna Lee, Sean T. Glenn, Devin Dressman, Antonios Papanicolau-Sengos, Felicia L. Lenzo, Carl Morrison & Razelle Kurzrock. (2020) Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. OncoImmunology 9:1.
Read now
Read now
Samantha Burugu, Dongxia Gao, Samuel Leung, Stephen K. Chia & Torsten O. Nielsen. (2018) TIM-3 expression in breast cancer. OncoImmunology 7:11.
Read now
Read now
Qi Chen, Tianhe Li & Wentao Yue. (2018) Drug response to PD-1/PD-L1 blockade: based on biomarkers. OncoTargets and Therapy 11, pages 4673-4683.
Read now
Read now
Catherine A. Sabatos-Peyton, James Nevin, Ansgar Brock, John D. Venable, Dewar J. Tan, Nasim Kassam, Fangmin Xu, John Taraszka, Luke Wesemann, Thomas Pertel, Nandini Acharya, Max Klapholz, Yassaman Etminan, Xiaomo Jiang, Yu-Hwa Huang, Richard S. Blumberg, Vijay K. Kuchroo & Ana C. Anderson. (2018) Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy. OncoImmunology 7:2.
Read now
Read now
Articles from other publishers (187)
Akbar Hasanzadeh, Arefeh Ebadati, Lida Dastanpour, Amir R. Aref, Parham Sahandi Zangabad, Alireza Kalbasi, Xiaofeng Dai, Geeta Mehta, Amir Ghasemi, Yousef Fatahi, Suhasini Joshi, Michael R. Hamblin & Mahdi Karimi. (2023) Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools. ACS Pharmacology & Translational Science 6:12, pages 1758-1779.
Crossref
Crossref
Keywan Mortezaee & Jamal Majidpoor. (2023) Alternative immune checkpoints in immunoregulatory profile of cancer stem cells. Heliyon 9:12, pages e23171.
Crossref
Crossref
Zhaoyun Liu, Xintong Xu, Hui Liu, Xianghong Zhao, Chun Yang & Rong Fu. (2023) Immune checkpoint inhibitors for multiple myeloma immunotherapy. Experimental Hematology & Oncology 12:1.
Crossref
Crossref
Jian Xu, Chen Gan, Sheng Yu, Senbang Yao, Wen Li & Huaidong Cheng. (2023) Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor. Clinical Breast Cancer.
Crossref
Crossref
Menglu Zhao, Chun-Yan Yan, Ya-Nan Wei & Xi-He Zhao. (2023) Breaking the mold: Overcoming resistance to immune checkpoint inhibitors. Antiviral Research 219, pages 105720.
Crossref
Crossref
Cheryl M. Cameron, Brian Richardson, Jackelyn B. Golden, Yee Peng Phoon, Banumathi Tamilselvan, Lukas Pfannenstiel, Samjhana Thapaliya, Gustavo Roversi, Xing-Huang Gao, Leah L. Zagore, Mark J. Cameron & Brian R. Gastman. (2023) A transcriptional evaluation of the melanoma and squamous cell carcinoma TIL compartment reveals an unexpected spectrum of exhausted and functional T cells. Frontiers in Oncology 13.
Crossref
Crossref
Arya Mariam Roy & Saby George. (2023)
Emerging resistance
vs.
losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena
. Cancer Drug Resistance 6:3, pages 642-55.
Crossref
Crossref
Basma Zohair, Dounia Chraa, Ibtissam Rezouki, Hamza Benthami, Ibtissam Razzouki, Mohamed Elkarroumi, Daniel Olive, Mehdi Karkouri & Abdallah Badou. (2023) The immune checkpoint adenosine 2A receptor is associated with aggressive clinical outcomes and reflects an immunosuppressive tumor microenvironment in human breast cancer. Frontiers in Immunology 14.
Crossref
Crossref
Jesse R. Qualliotine, Takuya Nakagawa, Sara Brin Rosenthal, Sayed Sadat, Carmen Ballesteros-Merino, Guorong Xu, Adam Mark, Art Nasamran, J. Silvio Gutkind, Kathleen M. Fisch, Theresa Guo, Bernard A. Fox, Zubair Khan, Alfredo A. Molinolo & Joseph A. Califano. (2023) A Network Landscape of HPVOPC Reveals Methylation Alterations as Significant Drivers of Gene Expression via an Immune-Mediated GPCR Signal. Cancers 15:17, pages 4379.
Crossref
Crossref
Qianyu Wang, Xiaofei Shen, Gang Chen & Junfeng Du. (2023) How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation. International Journal of Cancer 153:4, pages 709-722.
Crossref
Crossref
Ludovico Abenavoli, Michele Montori, Gianluca Svegliati Baroni, Maria Eva Argenziano, Francesca Giorgi, Giuseppe Guido Maria Scarlata, Francesca Ponziani & Emidio Scarpellini. (2023) Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors. Medicina 59:8, pages 1427.
Crossref
Crossref
Sudipta Biswas, Kai Kang, Kwok Peng Ng, Tomas Radivoyevitch, Kurt Schalper, Hua Zhang, Daniel J. Lindner, Anish Thomas, David MacPherson, Brian Gastman, David S. Schrump, Kwok-Kin Wong, Vamsidhar Velcheti & Yogen Saunthararajah. (2023) Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy. Cell Reports 42:8, pages 113016.
Crossref
Crossref
Keywan Mortezaee & Jamal Majidpoor. (2023) Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1. Biomedicine & Pharmacotherapy 163, pages 114824.
Crossref
Crossref
Danial Khayatan, Ahmed Hussain & Hamid Tebyaniyan. (2023) Exploring animal models in oral cancer research and clinical intervention: A critical review. Veterinary Medicine and Science 9:4, pages 1833-1847.
Crossref
Crossref
Yun Hu, Sébastien Paris, Narayan Sahoo, Genevieve Bertolet, Qi Wang, Qianxia Wang, Hampartsoum B. Barsoumian, Jordan Da Silva, Ailing Huang, Denaha J. Doss, David P. Pollock, Ethan Hsu, Nanez Selene, Claudia S. Kettlun Leyton, Tiffany A. Voss, Fatemeh Masrorpour, Shonik Ganjoo, Carola Leuschner, Jordan T. Pietz, Nahum Puebla-Osorio, Saumil Gandhi, Quynh-Nhu Nguyen, Jing Wang, Maria Angelica Cortez & James W. Welsh. (2023) Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection. JCI Insight 8:12.
Crossref
Crossref
Christina Bruss, Kerstin Kellner, Veruschka Albert, James A. Hutchinson, Stephan Seitz, Olaf Ortmann, Gero Brockhoff & Anja K. Wege. (2023) Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion. Cancers 15:9, pages 2615.
Crossref
Crossref
Tianqing Wang, Silu Sun, Xin Zeng & Jing Li. (2023) ICI-based therapies: A new strategy for oral potentially malignant disorders. Oral Oncology 140, pages 106388.
Crossref
Crossref
Christina Chen, Xin Liu, Che-Yu Chang, Helen Y. Wang & Rong-Fu Wang. (2023) The Interplay between T Cells and Cancer: The Basis of Immunotherapy. Genes 14:5, pages 1008.
Crossref
Crossref
Zhuo Zhang, Duoli Zhang, Fang Wang, Jiao Liu, Yuhong Sun, Songyot Anuchapreeda, Singkome Tima, Zhangang Xiao & Suwit Duangmano. (2023) Sema4D silencing increases the sensitivity of nivolumab to B16-F10 resistant melanoma via inhibiting the PI3K/AKT signaling pathway. PeerJ 11, pages e15172.
Crossref
Crossref
Marc C. Pulanco, Anne T. Madsen, Ankit Tanwar, Devin T. Corrigan & Xingxing Zang. (2023) Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. Cellular & Molecular Immunology 20:7, pages 694-713.
Crossref
Crossref
Fei-Fei Yang, Xue-Li Xu, Ting Hu, Jian-Quan Liu, Jin-Zhu Zhou, Li-Ying Ma & Hong-Min Liu. (2023) Lysine-Specific Demethylase 1 Promises to Be a Novel Target in Cancer Drug Resistance: Therapeutic Implications. Journal of Medicinal Chemistry 66:7, pages 4275-4293.
Crossref
Crossref
Su Jong Yu. (2023) Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. Pharmacology & Therapeutics 244, pages 108387.
Crossref
Crossref
Katarzyna Starska-Kowarska. (2023) The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. Cancers 15:6, pages 1642.
Crossref
Crossref
Pengpeng Zhang, Tianyin Wang, Hong Liu, Xingguo She, Ke Chen, Yujun Zhao & Yingzi Ming. (2023) Acute rejection was observed in a combination therapy of CTLA-4 and PD-1 inhibitors before liver transplantation: A case report and literature review. iLIVER.
Crossref
Crossref
Jianpei Zheng, Xueyuan Zhou, Yajuan Fu & Qi Chen. (2023) Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence. Cancers 15:4, pages 1314.
Crossref
Crossref
Vigdis Nygaard, Anne Hansen Ree, Vegar Johansen Dagenborg, Anne-Lise Børresen-Dale, Bjørn Edwin, Åsmund Avdem Fretland, Krzysztof Grzyb, Mads H. Haugen, Gunhild M. Mælandsmo & Kjersti Flatmark. (2023)
A
PRRX1
Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
. Cancer Research Communications 3:2, pages 235-244.
Crossref
Crossref
Hayato Nakamura, Satoru Konnai, Tomohiro Okagawa, Naoya Maekawa, Yamato Sajiki, Kei Watari, Kana Kamitani, Maya Saito, Yukinari Kato, Yasuhiko Suzuki, Shiro Murata & Kazuhiko Ohashi. (2023) Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus. Journal of Virology 97:1.
Crossref
Crossref
涛 秦. (2023) The Mechanism and Research Progress of PD-1 in Anti Atherosclerosis. Advances in Clinical Medicine 13:01, pages 847-853.
Crossref
Crossref
Neetu Kumari, Mettle Brahma & Mulaka Maruthi. 2023. Treatment Landscape of Targeted Therapies in Oncology. Treatment Landscape of Targeted Therapies in Oncology
95
134
.
Malte Renz & Oliver Dorigo. 2023. DiSaia and Creasman Clinical Gynecologic Oncology. DiSaia and Creasman Clinical Gynecologic Oncology
506
520.e7
.
Claudia Giannotta, Barbara Castella, Ezio Tripoli, Daniele Grimaldi, Ilaria Avonto, Mattia D’Agostino, Alessandra Larocca, Joanna Kopecka, Mariella Grasso, Chiara Riganti & Massimo Massaia. (2022) Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status. Frontiers in Immunology 13.
Crossref
Crossref
Besan H. Al-Saafeen, Ashraf Al-Sbiei, Ghada Bashir, Yassir A. Mohamed, Razan J. Masad, Maria J. Fernandez-Cabezudo & Basel K. al-Ramadi. (2022) Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer. Frontiers in Immunology 13.
Crossref
Crossref
Wentao Liu, Dianyun Ren, Wei Xiong, Xin Jin & Liang Zhu. (2022) A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Crossref
Yan Tie, Fan Tang, Yu-quan Wei & Xia-wei Wei. (2022) Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Shifa Zhang, Haibo Cai, Junjun Huang & Gongchao Wang. (2022)
Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor
PD‐L1
,
IDO
,
TIM
‐3,
FOXP3
+ and
CD8
expressions in patients with advanced esophageal squamous cell carcinoma
. Thoracic Cancer 13:23, pages 3284-3294.
Crossref
Crossref
Hao Chen, Kyle Molberg, Kelley Carrick, Shuang Niu, Glorimar Rivera Colon, Katja Gwin, Cheryl Lewis, Wenxin Zheng, Diego H. Castrillon & Elena Lucas. (2022) Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma. Modern Pathology 35:12, pages 1955-1965.
Crossref
Crossref
Keywan Mortezaee, Jamal Majidpoor & Sajad Najafi. (2022) VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated. Life Sciences 310, pages 121083.
Crossref
Crossref
Elnaz Rouzbahani, Jamal Majidpoor, Sajad Najafi & Keywan Mortezaee. (2022) Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Biomedicine & Pharmacotherapy 156, pages 113906.
Crossref
Crossref
Alec S. Britt, Caitlyn Huang & Chao H. Huang. (2022) Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?. Frontiers in Oncology 12.
Crossref
Crossref
John Moise, Jeevan Murthy, Dolma Dabir, Stephen Yu, Farah Kisto, Emily Herron & Sonikpreet Aulakh. (2022) Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade. Immuno 2:4, pages 671-691.
Crossref
Crossref
Wenjuan Ning, Thomas M. Marti, Patrick Dorn & Ren-Wang Peng. (2022) Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit. Frontiers in Oncology 12.
Crossref
Crossref
Sowmya Samudrala Venkatesiah, Dominic Augustine, Deepika Mishra, Neethi Gujjar, Vanishri C. Haragannavar, Kamran Habib Awan & Shankargouda Patil. (2022) Immunology of Oral Squamous Cell Carcinoma—A Comprehensive Insight with Recent Concepts. Life 12:11, pages 1807.
Crossref
Crossref
Marina Natoli, Klas Hatje, Pratiksha Gulati, Fabian Junker, Petra Herzig, Zhiwen Jiang, Iakov I Davydov, Markus Germann, Marta Trüb, Daniel Marbach, Adrian Zwick, Patrick Weber, Stefan Seeber, Mark Wiese, Didier Lardinois, Viola Heinzelmann-Schwarz, Robert Rosenberg, Lothar Tietze, Kirsten D Mertz, Pablo Umaña, Christian Klein, Laura Codarri-Deak, Henry Kao & Alfred Zippelius. (2022) Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors. Journal for ImmunoTherapy of Cancer 10:11, pages e005548.
Crossref
Crossref
Tobias Schatton, Yuta Itoh, Christina Martins, Erik Rasbach, Praveen Singh, Mariana Silva, Kyla Mucciarone, Markus V. Heppt, Jenna Geddes-Sweeney, Kate Stewart, Anne Brandenburg, Jennifer Liang, Charles J. Dimitroff, Martin C. MihmJrJr, Jennifer Landsberg, Christoph Schlapbach, Christine G. Lian, George F. Murphy, Thomas S. Kupper, Matthew R. Ramsey & Steven R. Barthel. (2022) Inhibition of Melanoma Cell–Intrinsic Tim-3 Stimulates MAPK-Dependent Tumorigenesis. Cancer Research 82:20, pages 3774-3784.
Crossref
Crossref
Riccardo Carloni, Alessandro Rizzo, Antonio Cusmai, Andrea Palloni, Alessandro Di Federico, Mariacristina Di Marco, Raffaella Massafra, Annarita Fanizzi, Gennaro Palmiotti & Giovanni Brandi. (2022) Advances in novel systemic therapies for advanced hepatocellular carcinoma. Future Medicinal Chemistry 14:20, pages 1455-1470.
Crossref
Crossref
Liliane Robillard, Mingxiang Liao, Minh Nguyen, Thomas C. Harding, Andrew D. Simmons & Rachel L. Dusek. (2022) The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models. Journal of Immunotherapy 45:8, pages 335-348.
Crossref
Crossref
Adnin Ashrafi, Zakia Akter, Pouya Modareszadeh, Parsa Modareszadeh, Eranda Berisha, Parinaz Sadat Alemi, Maria del Carmen Chacon Castro, Alexander R. Deese & Li Zhang. (2022) Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. Cancers 14:19, pages 4562.
Crossref
Crossref
Xiaoting Zhou, Yanghong Ni, Xiao Liang, Yi Lin, Biao An, Xiang He & Xia Zhao. (2022) Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Frontiers in Immunology 13.
Crossref
Crossref
Chenhang Yu, Qiang Li, Yu Zhang, Zhi-Fa Wen, Heng Dong & Yongbin Mou. (2022) Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma. Frontiers in Cell and Developmental Biology 10.
Crossref
Crossref
Soudeh Ghafouri-Fard, Ali Noie Alamdari, Yashar Noee Alamdari, Atefe Abak, Bashdar Mahmud Hussen, Mohammad Taheri & Elena Jamali. (2022) Role of PI3K/AKT pathway in squamous cell carcinoma with an especial focus on head and neck cancers. Cancer Cell International 22:1.
Crossref
Crossref
Lin Zhang, Chao Zhou, Songou Zhang, Xiaozhen Chen, Jian Liu, Fangming Xu & Wenqing Liang. (2022) Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. Frontiers in Oncology 12.
Crossref
Crossref
Yanina Arana, Rosa Isela Gálvez & Thomas Jacobs. (2022) Role of the PD-1/PD-L1 Pathway in Experimental Trypanosoma cruzi Infection and Potential Therapeutic Options. Frontiers in Immunology 13.
Crossref
Crossref
Juan L. Callejas-Valera, Daniel W. Vermeer, Christopher T. Lucido, Caitlin Williamson, Marisela Killian, Paola D. Vermeer, William C. Spanos & Steven F. Powell. (2022) Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma. Cancers 14:10, pages 2499.
Crossref
Crossref
A. M. Malkova, R. V. Orlova, N. V. Zhukova, A. R. Gubal & V. V. Sharoiko. (2022) Analysis of possible markers of effective antitumor cellular immune response before starting therapy with immune check-point inhibitors. Siberian journal of oncology 21:2, pages 109-117.
Crossref
Crossref
Tram M. Ta, Sajjaf Malik, Elizabeth M. Anderson, Amber D. Jones, Jocelyn Perchik, Maryann Freylikh, Luca Sardo, Zackary A. Klase & Taisuke Izumi. (2022) Insights Into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies. Frontiers in Microbiology 13.
Crossref
Crossref
Julia E. Fromme & Paola Zigrino. (2022) The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance. Frontiers in Molecular Biosciences 9.
Crossref
Crossref
Yaomei Tian, Daoyuan Xie & Li Yang. (2022) Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Hiroe Tada, Hideyuki Takahashi, Kanae Yamada, Kei Masuda, Yurino Nagata, Miho Uchida, Masato Shino, Shota Ida, Ikko Mito, Toshiyuki Matsuyama, Tetsunari Oyama, Ken-Ichiro Tatematsu, Hideki Sezutsu, Shigeki Takeda & Kazuaki Chikamatsu. (2021) Dynamic alterations of circulating T lymphocytes and the clinical response in patients with head and neck squamous cell carcinoma treated with nivolumab. Cancer Immunology, Immunotherapy 71:4, pages 851-863.
Crossref
Crossref
Annie Wai Yeeng Chai, Pei San Yee & Sok Ching Cheong. (2022) Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers. Frontiers in Oncology 12.
Crossref
Crossref
Elisa Ciraolo, Stefanie Althoff, Josefine Ruß, Stanislav Rosnev, Monique Butze, Miriam Pühl, Marco Frentsch, Lars Bullinger & Il-Kang Na. (2022) Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome. International Journal of Molecular Sciences 23:6, pages 3207.
Crossref
Crossref
Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola & Giovanni Brandi. (2022) Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?. Future Oncology 18:8, pages 1023-1034.
Crossref
Crossref
Xinjie Lu. (2022) Structure and Functions of T-cell Immunoglobulin-domain and Mucin- domain Protein 3 in Cancer. Current Medicinal Chemistry 29:11, pages 1851-1865.
Crossref
Crossref
I-Tsang Chiang, Yuan-Hao Lee, Zhao-Lin Tan, Fei-Ting Hsu & Hsi-Feng Tu. (2022) Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma. Biomedicine & Pharmacotherapy 147, pages 112661.
Crossref
Crossref
Mengmeng Ding, Yong-an Li, Zhimin Lu & Guoxin Hou. (2022) Identification of Potential Immune Checkpoint Inhibitor Targets in Gliomas via Bioinformatic Analyses. BioMed Research International 2022, pages 1-16.
Crossref
Crossref
晨晨 矫. (2022) Research Progress on the Relationship between Tumor Radiotherapy and TIM-3. Advances in Clinical Medicine 12:09, pages 8427-8433.
Crossref
Crossref
Ke Chen, Yun Gu, Yifan Cao, Hanji Fang, Kunpeng Lv, Xin Liu, Xudong He, Jieti Wang, Chao Lin, Hao Liu, Heng Zhang, Hongyong He, Jiejie Xu, He Li & Ruochen Li. (2021) TIM3+ cells in gastric cancer: clinical correlates and association with immune context. British Journal of Cancer 126:1, pages 100-108.
Crossref
Crossref
Irina Palacín-Aliana, Josefa Carrión-Navarro, Ángel Ayuso-Sacido & Noemí García-Romero. 2022. Translational Autoimmunity. Translational Autoimmunity
51
71
.
Shadia I. Jalal, Hirva Mamdani, Alaina M. Turchi & John J. Turchi. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
69
95
.
Xingxing Wang, Yan Wang, Ji Li, Tian Tian, Jinbo Li, Zijian Guo & Yan Zhang. (2021) T Cell‐Signaling‐Responsive Conjugate of Antibody with siRNA to Overcome Acquired Resistance to anti‐PD‐1 Immunotherapy. Advanced Therapeutics 5:1.
Crossref
Crossref
Beatriz Henriques, Fernando Mendes & Diana Martins. (2021) Immunotherapy in Breast Cancer: When, How, and What Challenges?. Biomedicines 9:11, pages 1687.
Crossref
Crossref
Han Chen, Ming Wang, Tonghui Weng, Yu Wei, Chuan Liu, Lei Yang, Ke Ren, Yi Tang, Zhaobing Tang & Xin Gou. (2021) The prognostic and clinicopathological significance of Tim-3 and PD-1 expression in the prognosis of upper urinary tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations 39:11, pages 743-753.
Crossref
Crossref
Lihua Liu, Mi Ae Lim, Seung-Nam Jung, Chan Oh, Ho-Ryun Won, Yan Li Jin, Yudan Piao, Hae Jong Kim, Jae Won Chang & Bon Seok Koo. (2021) The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer. Phytomedicine 92, pages 153758.
Crossref
Crossref
Elisabeth G. Vichaya, Bianca G. Ford, Jessica M. Moltenkine, Cullen M. Taniguchi, A. Phillip West & Robert Dantzer. (2021) Sex differences in the behavioral and immune responses of mice to tumor growth and cancer therapy. Brain, Behavior, and Immunity 98, pages 161-172.
Crossref
Crossref
R. Zou, Y. Wang, F. Ye, X. Zhang, M. Wang & S. Cui. (2021) Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. Clinical and Translational Oncology 23:11, pages 2237-2252.
Crossref
Crossref
Shaoming Zhu, Tian Zhang, Lei Zheng, Hongtao Liu, Wenru Song, Delong Liu, Zihai Li & Chong-xian Pan. (2021) Combination strategies to maximize the benefits of cancer immunotherapy. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Sanjay Chandrasekaran, Christopher Ronald Funk, Troy Kleber, Chrystal M. Paulos, Mala Shanmugam & Edmund K. Waller. (2021) Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ. Frontiers in Immunology 12.
Crossref
Crossref
Inka Brockhausen & Jacob Melamed. (2021) Mucins as anti-cancer targets: perspectives of the glycobiologist. Glycoconjugate Journal 38:4, pages 459-474.
Crossref
Crossref
Juwon Lee, Youngjin Han, Wenyu Wang, HyunA Jo, Heeyeon Kim, Soochi Kim, Kyung-Min Yang, Seong-Jin Kim, Danny N. Dhanasekaran & Yong Sang Song. (2021) Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy. Biomolecules 11:8, pages 1107.
Crossref
Crossref
Victor Cervera-Carrascon, Dafne C. A. Quixabeira, Joao M. Santos, Riikka Havunen, Ioanna Milenova, Jan Verhoeff, Camilla Heiniö, Sadia Zafar, Juan J. Garcia-Vallejo, Victor W. van Beusechem, Tanja D. de Gruijl, Aino Kalervo, Suvi Sorsa, Anna Kanerva & Akseli Hemminki. (2021) Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1. Frontiers in Immunology 12.
Crossref
Crossref
Houhui Shi, Kai Li, Yanghong Ni, Xiao Liang & Xia Zhao. (2021) Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A. Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti & Aung Naing. (2021) Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors. Clinical Cancer Research 27:13, pages 3620-3629.
Crossref
Crossref
Binghan Zhou, Yuan Gao, Peng Zhang & Qian Chu. (2021) Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies. Frontiers in Immunology 12.
Crossref
Crossref
Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, Justin T. Moyers, Michael A. Curran & Hussein A. Tawbi. (2021) Development of Immunotherapy Combination Strategies in Cancer. Cancer Discovery 11:6, pages 1368-1397.
Crossref
Crossref
Sathish K. R. Padi & Andrew S. Kraft. (2021) “Root”ing for successful T-ALL treatment. Blood 137:18, pages 2422-2423.
Crossref
Crossref
Lili Huang, Yu Xu, Juemin Fang, Weixing Liu, Jianhua Chen, Zhuqing Liu & Qing Xu. (2021) Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma. Frontiers in Immunology 12.
Crossref
Crossref
Camille M. Lake, Kelsey Voss, Bradly M. Bauman, Katherine Pohida, Timothy Jiang, Gabriela Dveksler & Andrew L. Snow. (2021) TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8+ T cells in conjunction with CEACAM1. Cell Death & Disease 12:4.
Crossref
Crossref
Michael W Knitz, Thomas E Bickett, Laurel B Darragh, Ayman J Oweida, Shilpa Bhatia, Benjamin Van Court, Shiv Bhuvane, Miles Piper, Jacob Gadwa, Adam C Mueller, Diemmy Nguyen, Varuna Nangia, Douglas G Osborne, Xiyuan Bai, Sarah E Ferrara, Mary-Keara Boss, Andrew Goodspeed, Matthew A Burchill, Beth A Jirón Tamburini, Edward D Chan, Curtis R Pickering, Eric T Clambey & Sana D Karam. (2021) Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis. Journal for ImmunoTherapy of Cancer 9:4, pages e001955.
Crossref
Crossref
Léa Paolini, Antonin Saldmann & Eric Tartour. (2021) Lymphocytes T-CD8 et immunothérapie anti-tumorale : rôle et Ciblage thérapeutique. Bulletin de l'Académie Nationale de Médecine 205:4, pages 354-363.
Crossref
Crossref
Peijie Wu, Wei Gao, Miao Su, Edouard C. Nice, Wenhui Zhang, Jie Lin & Na Xie. (2021) Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Sandra Ortiz-Cuaran, Jebrane Bouaoud, Andy Karabajakian, Jérôme Fayette & Pierre Saintigny. (2021) Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers. Frontiers in Oncology 11.
Crossref
Crossref
Nádia Ghinelli Amôr, Paulo Sérgio da Silva Santos & Ana Paula Campanelli. (2021) The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Xianghu Jiang, Guohong Liu, Yirong Li & Yunbao Pan. (2021) Immune checkpoint: The novel target for antitumor therapy. Genes & Diseases 8:1, pages 25-37.
Crossref
Crossref
A.M. Malkova, V.V. Sharoyko, N.V. Zhukova, A.R. Gubal & R.V. Orlova. (2021) Laboratory biomarkers of an effective antitumor immune response. Clinical significance.. Cancer Treatment and Research Communications 29, pages 100489.
Crossref
Crossref
Nicole L. Michmerhuizen, Jiayu Wang & J. Chad Brenner. 2020. Molecular Pharmacology. Molecular Pharmacology.
Jin-Yu Sun, Dengke Zhang, Songquan Wu, Min Xu, Xiao Zhou, Xiao-Jie Lu & Jiansong Ji. (2020) Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomarker Research 8:1.
Crossref
Crossref
Yang Yang, Yi Li, Huiyao Gu, Mengmeng Dong & Zhen Cai. (2020) Emerging agents and regimens for multiple myeloma. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Daixi Ren, Yuze Hua, Boyao Yu, Xin Ye, Ziheng He, Chunwei Li, Jie Wang, Yongzhen Mo, Xiaoxu Wei, Yunhua Chen, Yujuan Zhou, Qianjin Liao, Hui Wang, Bo Xiang, Ming Zhou, Xiaoling Li, Guiyuan Li, Yong Li, Zhaoyang Zeng & Wei Xiong. (2020) Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Molecular Cancer 19:1.
Crossref
Crossref
June Kyu Hwang, JinWoo Hong & Chae-Ok Yun. (2020) Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials. International Journal of Molecular Sciences 21:22, pages 8627.
Crossref
Crossref
Robert A. Gatenby & Joel S. Brown. (2020) The Evolution and Ecology of Resistance in Cancer Therapy. Cold Spring Harbor Perspectives in Medicine 10:11, pages a040972.
Crossref
Crossref
Zhengyi Wang & Xiaoying Wu. (2020) Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker. Cancer Medicine 9:21, pages 8086-8121.
Crossref
Crossref
Yuqing Cao, Xiaoyu Wang, Tianqiang Jin, Yu Tian, Chaoliu Dai, Crystal Widarma, Rui Song & Feng Xu. (2020) Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Signal Transduction and Targeted Therapy 5:1.
Crossref
Crossref
Reem Saleh & Eyad Elkord. (2020) Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. Seminars in Cancer Biology 65, pages 13-27.
Crossref
Crossref
Salman M. Toor, Varun Sasidharan Nair, Julie Decock & Eyad Elkord. (2020) Immune checkpoints in the tumor microenvironment. Seminars in Cancer Biology 65, pages 1-12.
Crossref
Crossref
Reem Saleh & Eyad Elkord. (2020) FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets. Cancer Letters 490, pages 174-185.
Crossref
Crossref
Xin-wei Qiao, Jian Jiang, Xin Pang, Mei-chang Huang, Ya-jie Tang, Xin-hua Liang & Ya-ling Tang. (2020) The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer. Frontiers in Immunology 11.
Crossref
Crossref
Anna Fialová, Vladimír Koucký, Martina Hajdušková, Kamila Hladíková & Radek Špíšek. (2020) Immunological Network in Head and Neck Squamous Cell Carcinoma—A Prognostic Tool Beyond HPV Status. Frontiers in Oncology 10.
Crossref
Crossref
Eleonore De Guillebon, Antoine Dardenne, Antonin Saldmann, Sylvie Séguier, Thi Tran, Lea Paolini, Celeste Lebbe & Eric Tartour. (2020) Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. International Journal of Cancer 147:6, pages 1509-1518.
Crossref
Crossref
Xiao-Jun Liu & Quan-Lin Guan. (2020) Mechanisms of resistance to immune checkpoint inhibitors. World Chinese Journal of Digestology 28:17, pages 857-864.
Crossref
Crossref
Thomas E. Bickett & Sana D. Karam. (2020) Tuberculosis–Cancer Parallels in Immune Response Regulation. International Journal of Molecular Sciences 21:17, pages 6136.
Crossref
Crossref
Liqin Yao, Gang Jia, Lingeng Lu, Ying Bao & Wenxue Ma. (2020) Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. International Immunopharmacology 85, pages 106628.
Crossref
Crossref
Cody Barbari, Tyler Fontaine, Priyanka Parajuli, Narottam Lamichhane, Silvia Jakubski, Purushottam Lamichhane & Rahul R. Deshmukh. (2020) Immunotherapies and Combination Strategies for Immuno-Oncology. International Journal of Molecular Sciences 21:14, pages 5009.
Crossref
Crossref
Reem Saleh, Salman M. Toor, Varun Sasidharan Nair & Eyad Elkord. (2020) Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression. Frontiers in Immunology 11.
Crossref
Crossref
Matthew Kraman, Mustapha Faroudi, Natalie L. Allen, Katarzyna Kmiecik, Daniel Gliddon, Claire Seal, Alexander Koers, Mateusz M. Wydro, Sarah Batey, Julia Winnewisser, Lesley Young, Mihriban Tuna, Jacqueline Doody, Michelle Morrow & Neil Brewis. (2020) FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity. Clinical Cancer Research 26:13, pages 3333-3344.
Crossref
Crossref
Weijun Wei, Dawei Jiang, Hye Jin Lee, Jonathan W. Engle, Hisaya Akiba, Jianjun Liu & Weibo Cai. (2020) ImmunoPET Imaging of TIM‐3 in Murine Melanoma Models. Advanced Therapeutics 3:7, pages 2000018.
Crossref
Crossref
Reem Saleh, Salman M. Toor, Dana Al-Ali, Varun Sasidharan Nair & Eyad Elkord. (2020) Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants. Genes 11:6, pages 703.
Crossref
Crossref
Amblessed E. Onuma, Hongji Zhang, Hai Huang, Terence M. Williams, Anne Noonan & Allan Tsung. (2020) Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. Gene Expression 20:1, pages 53-65.
Crossref
Crossref
Nandini Acharya, Catherine Sabatos-Peyton & Ana Carrizosa Anderson. (2020) Tim-3 finds its place in the cancer immunotherapy landscape. Journal for ImmunoTherapy of Cancer 8:1, pages e000911.
Crossref
Crossref
Yonina R. Murciano-Goroff, Allison Betof Warner & Jedd D. Wolchok. (2020) The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Research 30:6, pages 507-519.
Crossref
Crossref
Xiulan Lai, Wenrui Hao & Avner Friedman. (2020) TNF-α inhibitor reduces drug-resistance to anti-PD-1: A mathematical model. PLOS ONE 15:4, pages e0231499.
Crossref
Crossref
Mikolaj Kocikowski, Katarzyna Dziubek & Maciej Parys. (2020) Hyperprogression Under Immune Checkpoint-Based Immunotherapy—Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model. Cancers 12:4, pages 804.
Crossref
Crossref
Kangni Wu, Juan Feng, Yanghui Xiu, Zhifeng Li, Zhijuan Lin, Haijun Zhao, Hanyan Zeng, Weilin Xia, Lian Yu & Bing Xu. (2020) Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients. International Immunopharmacology 80, pages 106122.
Crossref
Crossref
Kristian M. Hargadon. (2020) Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints. Clinical and Translational Medicine 10:1, pages 374-411.
Crossref
Crossref
Victor C. Kok. (2020) Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer. Frontiers in Oncology 10.
Crossref
Crossref
Xiaobo Luo, Christopher R. Donnelly, Wang Gong, Blake R. Heath, Yuning Hao, Lorenza A. Donnelly, Toktam Moghbeli, Yee Sun Tan, Xin Lin, Emily Bellile, Benjamin A. Kansy, Thomas E. Carey, J. Chad Brenner, Lei Cheng, Peter J. Polverini, Meredith A. Morgan, Haitao Wen, Mark E. Prince, Robert L. Ferris, Yuying Xie, Simon Young, Gregory T. Wolf, Qianming Chen & Yu L. Lei. (2020) HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. Journal of Clinical Investigation 130:4, pages 1635-1652.
Crossref
Crossref
X. Qian, F. Leonard, Y. Wenhao, H. Sudhoff, T. K. Hoffmann, S. Ferrone, A. M. Kaufmann & A. E. Albers. (2020) Immunotherapeutics for head and neck squamous cell carcinoma stem cellsImmuntherapeutika gegen Kopf-Hals-Plattenepithelkarzinom-Stammzellen. HNO 68:2, pages 94-99.
Crossref
Crossref
Varun Sasidharan Nair, Salman M. Toor, Ghina Taouk, Gerald Pfister, Khalid Ouararhni, Nehad M. Alajez & Eyad Elkord. (2020) Pembrolizumab Interferes with the Differentiation of Human FOXP3+–Induced T Regulatory Cells, but Not with FOXP3 Stability, through Activation of mTOR. The Journal of Immunology 204:1, pages 199-211.
Crossref
Crossref
Stergios Doumas, Periklis G. Foukas, Panagiota Economopoulou, Ioannis Kotsantis & Amanda Psyrri. (2020) Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer. Oral Oncology 100, pages 104477.
Crossref
Crossref
Nicole C. Schmitt & Robert L. Ferris. 2020. Novel Therapies in Head and Neck Cancer: Beyond the Horizon. Novel Therapies in Head and Neck Cancer: Beyond the Horizon
117
142
.
Alain A. Vertès. 2020. Second Generation Cell and Gene-based Therapies. Second Generation Cell and Gene-based Therapies
515
578
.
Yiting Wang, Ping Wang & Jie Xu. 2020. Regulation of Cancer Immune Checkpoints. Regulation of Cancer Immune Checkpoints
347
398
.
Xu Qian, Thomas K. Hoffmann, Andreas M. Kaufmann & Andreas E. Albers. 2020. Cancer Immunology. Cancer Immunology
333
354
.
E. Dodagatta-Marri, D. S. Meyer, M. Q. Reeves, R. Paniagua, M. D. To, M. Binnewies, M. L. Broz, H. Mori, D. Wu, M. Adoumie, R. Del Rosario, O. Li, T. Buchmann, B. Liang, J. Malato, F. Arce Vargus, D. Sheppard, B. C. Hann, A. Mirza, S. A. Quezada, M. D. Rosenblum, M. F. Krummel, A. Balmain & R. J. Akhurst. (2019) α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Grace Wakabayashi, Yu-Ching Lee, Frank Luh, Chun-Nan Kuo, Wei-Chiao Chang & Yun Yen. (2019) Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. Journal of Biomedical Science 26:1.
Crossref
Crossref
Amanda R. Dancsok, Nokitaka Setsu, Dongxia Gao, Jean-Yves Blay, David Thomas, Robert G. Maki, Torsten O. Nielsen & Elizabeth G. Demicco. (2019) Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. Modern Pathology 32:12, pages 1772-1785.
Crossref
Crossref
Henning Zelba, Jens Bedke, Jörg Hennenlotter, Sven Mostböck, Markus Zettl, Thomas Zichner, Anoop Chandran, Arnulf Stenzl, Hans-Georg Rammensee & Cécile Gouttefangeas. (2019) PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma. Cancer Immunology Research 7:11, pages 1891-1899.
Crossref
Crossref
B.R. Heath, N.L. Michmerhuizen, C.R. Donnelly, K. Sansanaphongpricha, D. Sun, J.C. Brenner & Y.L. Lei. (2019) Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade. Journal of Dental Research 98:10, pages 1073-1080.
Crossref
Crossref
Chiara Massa & Barbara Seliger. (2019) The tumor microenvironment: Thousand obstacles for effector T cells. Cellular Immunology 343, pages 103730.
Crossref
Crossref
Jitka Fucikova, Jana Rakova, Michal Hensler, Lenka Kasikova, Lucie Belicova, Kamila Hladikova, Iva Truxova, Petr Skapa, Jan Laco, Ladislav Pecen, Ivan Praznovec, Michael J. Halaska, Tomas Brtnicky, Roman Kodet, Anna Fialova, Josephine Pineau, Alain Gey, Eric Tartour, Ales Ryska, Lorenzo Galluzzi & Radek Spisek. (2019) TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. Clinical Cancer Research 25:15, pages 4820-4831.
Crossref
Crossref
Reem Saleh & Eyad Elkord. (2019) Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Letters 457, pages 168-179.
Crossref
Crossref
Anliang Xia, Yan Zhang, Jiang Xu, Tailang Yin & Xiao-Jie Lu. (2019) T Cell Dysfunction in Cancer Immunity and Immunotherapy. Frontiers in Immunology 10.
Crossref
Crossref
Jie Deng, Jiannan Li, Aurelien Sarde, J. Louise Lines, Yu-Chi Lee, David C. Qian, Dov A. Pechenick, Richard Manivanh, Isabelle Le Mercier, Christopher H. Lowrey, Frederick S. Varn, Chao Cheng, David A. Leib, Randolph J. Noelle & Rodwell Mabaera. (2019) Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Cancer Immunology Research 7:7, pages 1079-1090.
Crossref
Crossref
Hyung-Don Kim & Su-Hyung Park. (2019) Immunological and clinical implications of immune checkpoint blockade in human cancer. Archives of Pharmacal Research 42:7, pages 567-581.
Crossref
Crossref
Emile Nibona, Gongyu Xu, Kongyue Wu, Hao Shen, Runshuai Zhang, Xiaomei Ke, Abdullah Al Hafiz, Zequn Wang, Chao Qi & Haobin Zhao. (2019) Identification, characterization, expression profiles of OlHavcr2 in medaka (Oryzias latipes). General and Comparative Endocrinology 277, pages 30-37.
Crossref
Crossref
Sankar Jagadeeshan, Manu Prasad, Sandra Ortiz-Cuaran, Vincent Gregoire, Pierre Saintigny & Moshe Elkabets. (2019) Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations. Trends in Cancer 5:6, pages 365-390.
Crossref
Crossref
Santiago Cabezas‐Camarero, Vanesa García‐Barberán, Melchor Sáiz‐Pardo Sanz, María Nieves Cabrera‐Martín, Jesús Gimeno‐Hernández & Pedro Pérez‐Segura. (2019) Durable intracranial and extracranial response to nivolumab with appearance of secondary resistance in a heavily pretreated patient with head and neck cancer. Head & Neck 41:6.
Crossref
Crossref
Charlene M. Fares, Eliezer M. Van Allen, Charles G. Drake, James P. Allison & Siwen Hu-Lieskovan. (2019) Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book:39, pages 147-164.
Crossref
Crossref
Simona Sivori, Paola Vacca, Genny Del Zotto, Enrico Munari, Maria Cristina Mingari & Lorenzo Moretta. (2019) Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cellular & Molecular Immunology 16:5, pages 430-441.
Crossref
Crossref
Jérôme Galon & Daniela Bruni. (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nature Reviews Drug Discovery 18:3, pages 197-218.
Crossref
Crossref
Xin Chen, Xiaomin Song, Kang Li & Tong Zhang. (2019) FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. Frontiers in Immunology 10.
Crossref
Crossref
Ye Qin, Shauna N. Vasilatos, Lin Chen, Hao Wu, Zhishen Cao, Yumei Fu, Min Huang, Anda M. Vlad, Binfeng Lu, Steffi Oesterreich, Nancy E. Davidson & Yi Huang. (2018) Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene 38:3, pages 390-405.
Crossref
Crossref
Qianyu Guo, Fan Huang, Christophe Goncalves, Sonia V. del Rincón & Wilson H. MillerJrJr. 2019. Immunotherapy of Cancer. Immunotherapy of Cancer
1
62
.
Arianna Draghi, Christopher Aled Chamberlain, Andrew Furness & Marco Donia. (2018) Acquired resistance to cancer immunotherapy. Seminars in Immunopathology 41:1, pages 31-40.
Crossref
Crossref
Xianda Zhao, Ce Yuan, John Markus Rieth, Dechen Wangmo & Subbaya Subramanian. 2019. Current Applications for Overcoming Resistance to Targeted Therapies. Current Applications for Overcoming Resistance to Targeted Therapies
97
129
.
Jeffrey Yang & Longqin Hu. (2018) Immunomodulators targeting the PD‐1/PD‐L1 protein‐protein interaction: From antibodies to small molecules. Medicinal Research Reviews 39:1, pages 265-301.
Crossref
Crossref
Noah Isakov. (2018) Cancer immunotherapy by targeting immune checkpoint receptors. World Journal of Immunology 8:1, pages 1-11.
Crossref
Crossref
Kyungsuk Jung, Hyunseok Kang & Ranee Mehra. (2018) Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). Cancers of the Head & Neck 3:1.
Crossref
Crossref
Feifei Liu, Yanning Liu & Zhi Chen. (2018) Tim-3 expression and its role in hepatocellular carcinoma. Journal of Hematology & Oncology 11:1.
Crossref
Crossref
Fernando Concha-Benavente, Benjamin Kansy, Jessica Moskovitz, Jennifer Moy, Uma Chandran & Robert L. Ferris. (2018) PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients. Cancer Immunology Research 6:12, pages 1548-1560.
Crossref
Crossref
Barry Paul, Shuqi Kang, Zhihong Zheng & Yubin Kang. (2018) The challenges of checkpoint inhibition in the treatment of multiple myeloma. Cellular Immunology 334, pages 87-98.
Crossref
Crossref
Weimin Lin, Miao Chen, Le Hong, Hang Zhao & Qianming Chen. (2018) Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. Frontiers in Oncology 8.
Crossref
Crossref
Ayman Oweida, Mohammad K. Hararah, Andy Phan, David Binder, Shilpa Bhatia, Shelby Lennon, Sanjana Bukkapatnam, Benjamin Van Court, Nomin Uyanga, Laurel Darragh, Hyun Min Kim, David Raben, Aik Choon Tan, Lynn Heasley, Eric Clambey, Raphael Nemenoff & Sana D. Karam. (2018) Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clinical Cancer Research 24:21, pages 5368-5380.
Crossref
Crossref
Chunping Ao & Kang Zeng. (2018) The role of regulatory T cells in pathogenesis and therapy of human papillomavirus-related diseases, especially in cancer. Infection, Genetics and Evolution 65, pages 406-413.
Crossref
Crossref
Natalia Arenas-Ramirez, Dilara Sahin & Onur Boyman. (2018) Epigenetic mechanisms of tumor resistance to immunotherapy. Cellular and Molecular Life Sciences 75:22, pages 4163-4176.
Crossref
Crossref
Chloé Grasselly, Morgane Denis, Aurore Bourguignon, Nolan Talhi, Doriane Mathe, Anne Tourette, Laurent Serre, Lars Petter Jordheim, Eva Laure Matera & Charles Dumontet. (2018) The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. Frontiers in Immunology 9.
Crossref
Crossref
Samantha Burugu, Amanda R. Dancsok & Torsten O. Nielsen. (2018) Emerging targets in cancer immunotherapy. Seminars in Cancer Biology 52, pages 39-52.
Crossref
Crossref
Yee Sun Tan, Kanokwan Sansanaphongpricha, Yuying Xie, Christopher R. Donnelly, Xiaobo Luo, Blake R. Heath, Xinyi Zhao, Emily Bellile, Hongxiang Hu, Hongwei Chen, Peter J. Polverini, Qianming Chen, Simon Young, Thomas E. Carey, Jacques E. Nör, Robert L. Ferris, Gregory T. Wolf, Duxin Sun & Yu L. Lei. (2018) Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. Clinical Cancer Research 24:17, pages 4242-4255.
Crossref
Crossref
Lydia Meder, Philipp Schuldt, Martin Thelen, Anna Schmitt, Felix Dietlein, Sebastian Klein, Sven Borchmann, Kerstin Wennhold, Ignacija Vlasic, Sebastian Oberbeck, Richard Riedel, Alexandra Florin, Kristina Golfmann, Hans A. Schlößer, Margarete Odenthal, Reinhard Buettner, Juergen Wolf, Michael Hallek, Marco Herling, Michael von Bergwelt-Baildon, H. Christian Reinhardt & Roland T. Ullrich. (2018) Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. Cancer Research 78:15, pages 4270-4281.
Crossref
Crossref
Yu Yu & Jiuwei Cui. (2018) Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review). Oncology Letters.
Crossref
Crossref
Kamila Hladíková, Simona Partlová, Vladimír Koucký, Jan Bouček, Jean-Francois Fonteneau, Michal Zábrodský, Ruth Tachezy, Marek Grega, Radek Špíšek & Anna Fialová. (2018) Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1. Oral Oncology 82, pages 75-82.
Crossref
Crossref
Hang Su, Huikang Xie, Chenyang Dai, Yijiu Ren, Yunlang She, Long Xu, Donglai Chen, Dong Xie, Liping Zhang, Gening Jiang & Chang Chen. (2018) Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma. Lung Cancer 121, pages 18-24.
Crossref
Crossref
C. David Pauza, Mei-Ling Liou, Tyler Lahusen, Lingzhi Xiao, Rena G. Lapidus, Cristiana Cairo & Haishan Li. (2018) Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local. Frontiers in Immunology 9.
Crossref
Crossref
J.J. Luo, C.D. Young, H.M. Zhou & X.J. Wang. (2018) Mouse Models for Studying Oral Cancer: Impact in the Era of Cancer Immunotherapy. Journal of Dental Research 97:6, pages 683-690.
Crossref
Crossref
Y.S. Tan, K. Sansanaphongpricha, M.E.P. Prince, D. Sun, G.T. Wolf & Y.L. Lei. (2018) Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer. Journal of Dental Research 97:6, pages 627-634.
Crossref
Crossref
Jin‐Cheng Wang, Yong Xu, Zheng‐Ming Huang & Xiao‐Jie Lu. (2018) T cell exhaustion in cancer: Mechanisms and clinical implications. Journal of Cellular Biochemistry 119:6, pages 4279-4286.
Crossref
Crossref
Sophie Outh-Gauer, Marie Alt, Christophe Le Tourneau, Jérémy Augustin, Chloé Broudin, Cassandre Gasne, Thomas Denize, Haitham Mirghani, Elizabeth Fabre, Madeleine Ménard, Florian Scotte, Eric Tartour & Cécile Badoual. (2018) Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. Cancer Treatment Reviews 65, pages 54-64.
Crossref
Crossref
Daniela S. Thommen & Ton N. Schumacher. (2018) T Cell Dysfunction in Cancer. Cancer Cell 33:4, pages 547-562.
Crossref
Crossref
Clémence Granier, Alain Gey, Charles Dariane, Arnaud Mejean, Marc-Olivier Timsit, Charlotte Blanc, Virginie Verkarre, Camélia Radulescu, Elisabeth Fabre, Yann Vano, Stéphane Oudard, Cécile Badoual & Éric Tartour. (2018) Tim-3. médecine/sciences 34:3, pages 231-237.
Crossref
Crossref
Hridesh Banerjee & Lawrence P. Kane. (2018) Immune regulation by Tim-3. F1000Research 7, pages 316.
Crossref
Crossref
Michael Flynn, Kate Young, David Cunningham & Naureen Starling. (2018) The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. Therapeutic Advances in Medical Oncology 10, pages 175883591878622.
Crossref
Crossref
Khalid Alamoud & Maria A. Kukuruzinska. 2018. Molecular Determinants of Head and Neck Cancer. Molecular Determinants of Head and Neck Cancer
491
524
.
Nicholas L Syn, Michele W L Teng, Tony S K Mok & Ross A Soo. (2017) De-novo and acquired resistance to immune checkpoint targeting. The Lancet Oncology 18:12, pages e731-e741.
Crossref
Crossref
Benjamin A. Kansy, Fernando Concha-Benavente, Raghvendra M. Srivastava, Hyun-Bae Jie, Gulidanna Shayan, Yu Lei, Jessica Moskovitz, Jennifer Moy, Jing Li, Sven Brandau, Stephan Lang, Nicole C. Schmitt, Gordon J. Freeman, William E. Gooding, David A. Clump & Robert L. Ferris. (2017) PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer Research 77:22, pages 6353-6364.
Crossref
Crossref
Kate Poropatich, Joel Fontanarosa, Suchitra Swaminathan, Dave Dittmann, Siqi Chen, Sandeep Samant & Bin Zhang. (2017) Comprehensive T-cell immunophenotyping and next-generation sequencing of human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinomas. The Journal of Pathology 243:3, pages 354-365.
Crossref
Crossref
Li-Hua Luo, Dong-Mei Li, Yan-Ling Wang, Kang Wang, Li-Xin Gao, Shuang Li, Ji-Gang Yang, Chun-Lin Li, Wei Feng & Hong Guo. (2017) Tim3/galectin-9 alleviates the inflammation of TAO patients via suppressing Akt/NF-kB signaling pathway. Biochemical and Biophysical Research Communications 491:4, pages 966-972.
Crossref
Crossref
Zhiyong Wang, Juan Callejas Valera, Xuefeng Zhao, Qianming Chen & J. Silvio Gutkind. (2017) mTOR co-targeting strategies for head and neck cancer therapy. Cancer and Metastasis Reviews 36:3, pages 491-502.
Crossref
Crossref
Hyun-Bae Jie, Raghvendra M. Srivastava, Athanassios Argiris, Julie E. Bauman, Lawrence P. Kane & Robert L. Ferris. (2017) Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients. Cancer Immunology Research 5:5, pages 408-416.
Crossref
Crossref
Clemence Granier, Eleonore De Guillebon, Charlotte Blanc, Helene Roussel, Cecile Badoual, Elia Colin, Antonin Saldmann, Alain Gey, Stephane Oudard & Eric Tartour. (2017) Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open 2:2, pages e000213.
Crossref
Crossref